Literature DB >> 7690745

Cardiopulmonary responses to chronic hypoxia in transgenic mice that overexpress ANP.

J R Klinger1, R D Petit, L A Curtin, R R Warburton, D S Wrenn, M E Steinhelper, L J Field, N S Hill.   

Abstract

Elevated plasma atrial natriuretic peptide (ANP) levels have been shown to blunt pulmonary hemodynamic responses to chronic hypoxia, but whether elevated circulating ANP levels negatively feedback on cardiac expression of the ANP gene is unknown. Using a recently developed strain of transgenic mouse (TTR-ANF) that expresses a transthyretin promoter-ANP fusion gene in the liver, we studied the effect of chronically elevated plasma ANP levels on cardiac hypertrophic and pulmonary hemodynamic responses and expression of the endogenous cardiac ANP gene during chronic hypoxia. Plasma ANP levels were 10-fold higher in TTR-ANF mice than in their non-transgenic littermates. After 3 wk of hypobaric hypoxia (0.5 atm), right ventricular hypertrophy and pulmonary hypertension had developed in both groups of mice, but TTR-ANF mice had lower right ventricle-to-left ventricle plus septum weight ratios (0.39 +/- 0.01 vs. 0.45 +/- 0.02), right ventricular systolic pressures (25 +/- 2 vs. 29 +/- 2 mmHg), and lung dry weight-to-body weight ratios (0.48 +/- 0.03 vs. 0.57 +/- 0.01 mg/g) and less muscularization of peripheral pulmonary vessels (8.3 +/- 1.4 vs. 17.4 +/- 2.5%) than nontransgenic controls. Right atrial and ventricular steady-state ANP mRNA levels were the same in both groups of mice under normoxic and hypoxic conditions despite much higher plasma ANP levels and less pulmonary hypertension in TTR-ANF mice. We conclude that chronically elevated plasma ANP levels attenuate the development of hypoxic pulmonary hypertension in mice but do not suppress cardiac expression of the endogenous ANP gene under normoxic conditions nor blunt the upregulation of right ventricular ANP expression during chronic hypoxia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690745     DOI: 10.1152/jappl.1993.75.1.198

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  14 in total

1.  A friend within the heart: natriuretic peptide receptor signaling.

Authors:  Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice.

Authors:  J W Knowles; G Esposito; L Mao; J R Hagaman; J E Fox; O Smithies; H A Rockman; N Maeda
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

3.  Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis.

Authors:  T Nishikimi; S Nagata; T Sasaki; S Tomimoto; H Matsuoka; S Takishita; K Kitamura; A Miyata; H Matsuo; K Kangawa
Journal:  Heart       Date:  1997-10       Impact factor: 5.994

4.  Deficiency of actinin-associated LIM protein alters regional right ventricular function and hypertrophic remodeling.

Authors:  Ilka Lorenzen-Schmidt; Andrew D McCulloch; Jeffrey H Omens
Journal:  Ann Biomed Eng       Date:  2005-07       Impact factor: 3.934

5.  Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice.

Authors:  S F Yet; M A Perrella; M D Layne; C M Hsieh; K Maemura; L Kobzik; P Wiesel; H Christou; S Kourembanas; M E Lee
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

6.  Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.

Authors:  Reshma S Baliga; Lan Zhao; Melanie Madhani; Belen Lopez-Torondel; Cristina Visintin; David Selwood; Martin R Wilkins; Raymond J MacAllister; Adrian J Hobbs
Journal:  Am J Respir Crit Care Med       Date:  2008-08-08       Impact factor: 21.405

7.  Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia.

Authors:  J S Thompson; W Sheedy; A H Morice
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 8.  Future perspectives for the treatment of pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Robyn J Barst; Raymond L Benza; Hunter C Champion; Karen A Fagan; Friedrich Grimminger; Marc Humbert; Gérald Simonneau; Duncan J Stewart; Carlo Ventura; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

9.  Protection of oral hydrogen water as an antioxidant on pulmonary hypertension.

Authors:  Bin He; Yufeng Zhang; Bo Kang; Jian Xiao; Bing Xie; Zhinong Wang
Journal:  Mol Biol Rep       Date:  2013-08-18       Impact factor: 2.316

10.  Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats.

Authors:  Jian Guan; Allen C Clermont; Loc-Duyen Pham; Tuna Ustunkaya; Alexey S Revenko; A Robert MacLeod; Edward P Feener; Fabrício Simão
Journal:  Transl Stroke Res       Date:  2021-07-09       Impact factor: 6.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.